## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and conclusions as stated in the abstract; no methods, figures, tables, or supplementary materials were provided for evaluation
- **Shared manuscript claim summary** The authors present TFXcan, a framework that correlates genetically predicted TF binding with phenotypes to nominate TF-tissue pairs relevant to complex traits. Within this framework, they introduce Enpact, a deep learning approach integrating Enformer and IMPACT to infer personalized TF-binding events. They apply this to prostate cancer risk, identifying implicated TFs at risk loci and clusters of TF-tissue pairs ("programs") via matrix decomposition. They claim TFXcan is the first method capable of predicting TF binding from genotype data at scale.
- **Visible evidence base** Abstract text only. No figures, tables, methods descriptions, or supplementary data were supplied.
- **Missing materials affecting confidence** Full manuscript, methods details, validation results, performance benchmarks, comparison to existing tools, statistical details, and all figures and tables. Without these, the core claims cannot be independently assessed.

## Reviewer
- **Overall assessment** The abstract describes a potentially valuable framework for linking TF binding to complex trait risk, with a plausible computational pipeline. However, the abstract alone provides insufficient detail to evaluate the validity, novelty, or robustness of the approach. Key claims, particularly the "first method" assertion and the biological relevance of identified programs, are not supported by the evidence provided in this submission. The work may be of interest to the genomics and statistical genetics community, but the current evidence base is too limited to establish the case.
- **Who would be interested in the results, and why** Statistical geneticists, computational biologists, and researchers studying gene regulation in complex diseases, particularly those focused on prostate cancer. The framework could be of interest to those seeking to interpret GWAS loci through a regulatory lens, and to developers of deep learning methods for genomics.
- **Major strengths** The conceptual integration of genotype-based TF binding prediction with GWAS trait correlation is a sensible and potentially impactful direction. The use of deep learning to scale TF binding prediction across many TF-tissue pairs is a practical advance if validated. The focus on "programs" of TF-tissue pairs adds a systems-level perspective that could yield biological insight.
- **Major Concerns**  
  - R1-M1  
  - R1-M2  
  - R1-M3
- **Minor Comments**  
  - R1-m1  
  - R1-m2  
  - R1-m3
- **Technical failings that need to be addressed before the case is established** The abstract does not provide any quantitative evidence of prediction accuracy, validation against experimental TF binding data, or comparison to existing methods. The claim of being "first" is unsubstantiated without a literature survey. The biological interpretation of "programs" is not supported by any functional validation or enrichment analysis described in the abstract.
- **Assessment against Nature-style criteria**  
  - Originality: The combination of genotype-based TF binding prediction with GWAS correlation is not entirely new in concept, but the scale and integration may offer novelty. However, the abstract does not clearly differentiate from prior work such as IMPACT or other TF binding prediction methods.  
  - Scientific importance: If validated, the framework could aid interpretation of many GWAS loci, which is a significant need. However, importance is not established from the abstract alone.  
  - Interdisciplinary readership: The work bridges deep learning, statistical genetics, and regulatory biology, which could attract a broad readership. The abstract is accessible but lacks technical depth.  
  - Technical soundness: Cannot be assessed. No methods, validation, or performance metrics are provided.  
  - Readability for nonspecialists: The abstract is reasonably clear, though terms like "Enpact" and "programs" are introduced without sufficient context.
- **Recommendation posture** Currently not established from the provided evidence. The abstract is promising but insufficient for a positive recommendation. A full manuscript with validation and comparisons would be required to assess the claims.

### Major Concerns

- **Concern ID** R1-M1  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Technical soundness  
- **Claim pointer** The authors claim that Enpact, a deep learning approach integrating Enformer and IMPACT, can infer personalized TF-binding events and that TFXcan correlates these with phenotypes.  
- **Evidence pointer** Abstract only; no methods or validation sections provided  
- **Concern** The abstract provides no details on how Enpact is trained, what data it uses, how accuracy is measured, or whether predictions are validated against experimental TF binding data. Without this, the reliability of the predicted binding profiles is unknown.  
- **Why it matters** The entire framework depends on the accuracy of TF binding predictions. If these are not validated, any downstream correlations with phenotypes are uninterpretable.  
- **Resolution test** Provide validation results comparing Enpact predictions to experimental ChIP-seq or similar data, including metrics such as AUROC or correlation, and describe the training and evaluation procedure in detail.

- **Concern ID** R1-M2  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Originality and positioning  
- **Claim pointer** The authors state that "TFXcan represents the first method capable of predicting TF binding from genotype data at scale."  
- **Evidence pointer** Abstract only; no literature comparison provided  
- **Concern** The claim of being "first" is a strong assertion that requires a thorough comparison to existing methods. Prior work, including IMPACT itself and other genotype-based regulatory prediction tools, may already perform similar tasks. The abstract does not acknowledge or differentiate from these.  
- **Why it matters** If the claim is inaccurate, it undermines the novelty and positioning of the work. Even if accurate, the claim needs substantiation.  
- **Resolution test** Provide a systematic comparison to existing methods, including performance benchmarks and a clear statement of what is genuinely new. If the claim is retained, it must be supported by a literature review.

- **Concern ID** R1-M3  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Biological interpretation  
- **Claim pointer** The authors claim that matrix decomposition reveals clusters of TF-tissue pairs, termed "programs," acting as candidate drivers of disease risk.  
- **Evidence pointer** Abstract only; no results or figures provided  
- **Concern** The abstract does not describe how these programs are derived, what statistical criteria define them, or whether they are validated in any way. The claim that they are "candidate drivers" is speculative without functional evidence or enrichment analysis.  
- **Why it matters** The biological relevance of the findings is a key selling point. Without validation, the programs could be statistical artifacts.  
- **Resolution test** Provide details on the matrix decomposition method, criteria for program identification, and validation such as enrichment for known regulatory elements, eQTL overlap, or functional assays.

### Minor Comments

- **Concern ID** R1-m1  
- **Severity** Minor  
- **Axis** Clarity  
- **Affected element** Terminology  
- **Evidence pointer** Abstract  
- **Issue** The term "Enpact" is introduced without explanation of its origin or meaning, which may confuse readers.  
- **Required correction** Define the name or provide a brief rationale for the choice.

- **Concern ID** R1-m2  
- **Severity** Minor  
- **Axis** Reproducibility  
- **Affected element** Data availability  
- **Evidence pointer** Abstract  
- **Issue** No mention of data or code availability, which is important for reproducibility.  
- **Required correction** State where the code, models, and data will be made available.

- **Concern ID** R1-m3  
- **Severity** Minor  
- **Axis** Scope  
- **Affected element** Generalizability  
- **Evidence pointer** Abstract  
- **Issue** The application is limited to prostate cancer, and it is unclear if the framework generalizes to other traits.  
- **Required correction** Briefly discuss potential generalizability or note it as a limitation.

## Risk / unsupported claims
- The claim that TFXcan is the "first method" for predicting TF binding from genotype data at scale is unsupported without a literature comparison.
- The claim that identified "programs" are "candidate drivers of disease risk" is unsupported without functional validation or enrichment analysis.
- The accuracy and reliability of Enpact predictions are unassessable from the abstract alone.
- The statistical significance and robustness of the TF-tissue associations with prostate cancer risk are not reported.